An in vitro model of light chain deposition disease

Kidney International

Volumn 75, Issue 6, 2009, Pages 634-645

  Keeling, John ^a   Herrera, Guillermo A ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nephrocor   (United States)

Author keywords

Glomerulosclerosis; Light chain deposition disease; MMP 7; PDGF ; Tenascin C; TGF

Indexed keywords

AMYLOID; IMMUNOGLOBULIN LIGHT CHAIN; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; SCLEROPROTEIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN DEPOSITION; IN VITRO STUDY; KIDNEY DISEASE; LIGHT CHAIN DEPOSITION DISEASE; MESANGIUM CELL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETIC NEPHROPATHIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MATRIX METALLOPROTEINASE 7; MESANGIAL CELLS; PLATELET-DERIVED GROWTH FACTOR; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 59949097904     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.504     Document Type: Article

References (52)

1. Antonovych T, Linc C, Parrish E et al. Light chain deposits in multiple myeloma (abstract). Lab Invest 1974; 30: 370A.
2. Randall RE, Williamson Jr WC, Mullinax F et al. Manifestations of systemic light chain deposition. Am J Med 1976; 60: 293-299.
3. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patient's bedside to the research laboratory. Ann Diag Pathol 2000; 4: 174-200.
4. Herrera GA, Joseph L, Gu X et al. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004; 128: 875-879.
5. Iványi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990; 114: 986-987.
6. Ronco PM, Alyanakian M-A, Mougenot B et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001; 12: 1558-1565.
7. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 2002; 22: 319-330.
8. Turbat-Herrera EA, Isaac J, Sanders PW et al. Integrated expression of glomerular extracellular matrix proteins and β1 integrins in monoclonal light chain-related renal diseases. Mod Pathol 1997; 10: 485-495.
9. Sanders PW, Herrera GA, Kirk KA et al. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991; 64: 527-537.
10. Zhu L, Herrera GA, Murphy-Ullrich JE et al. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 1995; 147: 375-385.
11. Teng J, Zhang PL, Russell WJ et al. Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains. Nephron Physiol 2003; 200: 423-428.
12. Sugiyama H, Kashihara N, Makino H et al. Apoptosis in glomerular sclerosis. Kidney Int 1996; 49: 103-111.
13. Tagouri YM, Sanders PW, Zhu L et al. Glomerulopathic monoclonal light chains potentiate mesangial cell apoptosis in vitro (abstract). Lab Invest 1995; 92: 161A.
14. Herrera GA, Shultz J, Soong S-J et al. Growth factors in monoclonal light chain-related renal diseases. Hum Pathol 1994; 25: 883-892.
15. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200: 423-428.
16. Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J Biol Chem 2005; 280: 26641-26644.
17. Bourdon MA, Wikstrand CJ, Furthmayr H et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983; 43: 2796-2805.
18. Kammerer RA, Schulthess T, Landwehr R et al. Tenascin-C hexabrachion assembly is a sequential twostep process initiated by coiled-coil alphahelices. J Biol Chem 1998; 273: 10602-10608.
19. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-259.
20. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol 2004; 36: 986-990.
21. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499.
22. Joester A, Faissner A. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. J Biol Chem 1999; 274: 17144-17151.
23. Kadar A, Tokes AM, Kulka J et al. Extracellular matrix components in breast carcinomas. Semin Cancer Biol 2002; 12: 243-257.
24. Dalkowski A, Schuppan D, Orfanos CE et al. Increased expression of tenascin C by keloids in vivo and in vitro. Br J Dermatol 1999; 141: 50-56.
25. Truong LD, Pindur J, Barrios R et al. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994; 45: 201-210.
26. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995; 147: 1759-1769.
27. Isaac J, Kerby JD, Russell WJ et al. In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid 1998; 5: 238-246.
28. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev 2002; 2: 161-174.
29. Parks WC, Mecham RP. Matrix Metalloproteinases. Academic Press: San Diego, 1998.
30. Murphy G, Knauper V, Cowell S et al. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci 1999; 878: 25-39.
31. Imai K, Yokohama Y, Nakanishi I et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. J Biol Chem 1995; 270: 6691-6697.
32. Thiennu HV, Zena W. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14: 2123-2133.
33. Gaire M, Magbanua Z, McDonnell S et al. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 1994; 269: 2032-2040.
34. Parks WC. Matrix metalloproteinases in repair. Wound Rep Reg 1999; 7: 423-432.
35. Bernardo M, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinases-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003; 374: 739-745.
36. Pardo A, Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol 2005; 37: 283-288.
37. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16: 558-564.
38. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int 2005; 68: 1590-1603.
39. Shiomi T, Inoki I, Kataoka F et al. Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151. Lab Invest 2005; 85: 1489.
40. Matrisian LM. Matrix metalloproteinases. Curr Biol 2000; 10: R692.
41. Imai K, Kusakabeb M, Sakakurac T et al. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994; 352: 216-218.
42. Guiffrida A, Scarpa S, Birarelli P et al. The interaction of tenascin-C with fibronectin modulates the migration and specific activity in human mesothelial cell lines of different histotype. Int J Oncol 2004; 25: 745-750.
43. Siri A, Knäuper V, Veirana N et al. Different susceptibility of small and large human tenascin-C isoform to degradation by matrix metalloproteinases. J Biol Chem 1995; 270: 8650-8654.
44. Ahmed AK, Haylor JL, El Nahas AM et al. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007; 71: 755-763.
45. Joester A, Faissner A. The structure and function of tenascins in the nervous system. Matrix Biol 2001; 20: 13-22.
46. Crossin KL. Cytotactin binding: inhibition of stimulated proliferation and intracellular alkalinization in fibroblasts. Proc Natl Acad Sci USA 1991; 88: 11403-11407.
47. Keeling J, Herrera GA. MMP-7 expression and the accumulation of tenascin in light chain deposition disease mesangial nodules. J Am Soc Nephrol 2005; 16: 608A.
48. McLennan SV, Kelly DJ, Schache M et al. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? Kidney Int 2007; 72: 481-488.
49. Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 2000; 35: 1-5.
50. Hotta O, Taguma Y. Resolution of nodular glomerular lesions in a patient with light chain nephropathy. Nephron 2002; 91: 504-505.
51. Harper PA, Robinson JM, Hoover RL et al. Improved methods for culturing rat glomerular cells. Kidney Int 1984; 26: 875-880.
52. Shi S, Coote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997; 45: 327-343.